AZU1 and type 2 diabetes mellitus: Numerous pieces of evidence have indicated that some key antimicrobial components of NETs, including MPO and azurocidin (CAP37), are downregulated in diabetic patients with poor glycemic control,38 which could explain the increased susceptibility to CR-hvKP in T2D patients.